Clinical Trial

Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis

Name: Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis — clinical trial record (NCT07471503)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CONTINUUM-MF

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The investigators evaluate the efficacy and safety of Gecacitinib in patients with myelofibrosis (MF) before, during, and after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Trial Details

NCT Number	NCT07471503
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Myelofibrosis (MF), HSCT
Enrollment	39 participants
Start Date	2026-03-16
Primary Completion	2029-04-01 (estimated)
Study Completion	2030-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-13